A river model to map convergent cancer evolution and guide therapy in RCC. (Q38622920)

4 September 2017

title

A river model to map convergent cancer evolution and guide therapy in RCC. (English)

1 reference

4 September 2017

0 references

Elizabeth Y Wei

1 reference

4 September 2017

James J Hsieh

series ordinal

1 reference

4 September 2017

language of work or name

English

0 references

publication date

3 November 2015

1 reference

4 September 2017

published in

Nature Reviews Urology

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

706-712

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The molecular biology of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Head and neck cancer in 2010: Maximizing survival and minimizing toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Landmarks in the diagnosis and treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Reliable detection of subclonal single-nucleotide variants in tumour cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intratumor heterogeneity: seeing the wood for the trees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Parallel evolution of tumour subclones mimics diversity between tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intratumor heterogeneity: evolution through space and time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

A clear picture of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Molecular genetics of clear-cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Cancer heterogeneity: implications for targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Cancer as an evolutionary and ecological process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The VHL/HIF axis in clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The "seed and soil" hypothesis revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Intra-tumour heterogeneity: a looking glass for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

ERBB4 is over-expressed in human colon cancer and enhances cellular transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Evolution of resistance during clonal expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

A microenvironmental model of carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

21 January 2018

Of cancer and cave fish

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.260

Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26526752

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2015.260

1 reference

Dimensions Publication ID

4 September 2017

1031695553

0 references

Fatcat ID

release_zeytjuibwzgr5cj4vhice5b5ne

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zeytjuibwzgr5cj4vhice5b5ne

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference